SOLICITATION NOTICE
Q -- Gene-to-Antibody and CloneArk Plasmid Preparation Services
- Notice Date
- 2/1/2023 2:54:49 PM
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- NOI-NIAID-2160691
- Response Due
- 2/7/2023 2:00:00 PM
- Point of Contact
- Dana Monroe, Phone: 4063759814
- E-Mail Address
-
dana.monroe@nih.gov
(dana.monroe@nih.gov)
- Description
- PRE-SOLICITATION NOTICE � NOTICE OF INTENT NOI-NIAID-2160691 NAICS � 541380, Testing Laboratories This is a Notice of Intent, not a request for proposal.� The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with GenScript USA Inc to procure gene-to-antibody and CloneArk plasmid preparation services for on-going studies to be used in the design of new vaccine candidates and to be tested for the ability to prevent SARS-CoV-2 and Malaria. The Laboratory of Immunogenetics (LIG) focuses on the cellular and molecular mechanisms that underlie the signaling functions in immune cells. The Antibody Biology Unit (ABU) of the Laboratory of Immunogenetics (LIG), focuses on the cellular and molecular mechanisms that underlie the signaling functions in immune cells. LIG has recently expanded its focus to include work on isolating human monoclonal antibodies against different infectious diseases including SARS-CoV-2 and Malaria. These antibodies and plasmids can be used to design new vaccine candidates and be tested for the ability to prevent SARS-CoV-2 and Malaria. LIG has been using GenScript for the past few years for production of human monoclonal antibodies and plasmids, as required on this acquisition. The speed of production and delivery, as well as the quality of the products meets the requirements of the government. This requirement is for custom antibody and plasmid preparation services to produce human monoclonal antibodies and plasmids for a large number of antibody heavy and light chains. The studies conducted after these services are imperative to continue analysis testing and make determinations proceeding the vaccine candidate phase. The antibodies and plasmids used in the testing services are not commercially available, and due to their very specific requirements and modifications, are produced by a very limited number of companies. GenScript is the only company that can properly prepare all of the lengthy and specific proteins of interest required to fulfill this project. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.� All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2160691 to Dana Monroe at dana.monroe@nih.gov, by 5:00 pm eastern standard time Tuesday, February 7, 2023. �All responses received by the closing date of this synopsis will be considered by the Government.� A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/460fb58ef1b44640a9e461b64205aed1/view)
- Place of Performance
- Address: Rockville, MD 20852, USA
- Zip Code: 20852
- Country: USA
- Zip Code: 20852
- Record
- SN06579024-F 20230203/230201230111 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |